Rimer, Jeffrey D.2022-06-18August 2022021-08August 202Portions of this document appear in: Kim, D., Rimer, J. D., & Asplin, J. R. (2019). Hydroxycitrate: a potential new therapy for calcium urolithiasis. Urolithiasis, 47(4), 311-320; and in: Kim, D., Olympiou, C., McCoy, C. P., Irwin, N. J., & Rimer, J. D. (2020). Time‐Resolved Dynamics of Struvite Crystallization: Insights from the Macroscopic to Molecular Scale. Chemistry–A European Journal, 26(16), 3555-3563; and in: Kim, D., Moore, J., McCoy, C. P., Irwin, N. J., & Rimer, J. D. (2020). Engaging a Battle on Two Fronts: Dual Role of Polyphosphates as Potent Inhibitors of Struvite Nucleation and Crystal Growth. Chemistry of Materials, 32(19), 8672-8682.https://hdl.handle.net/10657/9375The development of new methods to prevent mineral scale formation can have significant impact on natural, biological, and industrial process. A ubiquitous approach to regulating crystal formation is through the use of modifiers, which are (macro)molecules that interact with crystals to inhibit nucleation and/or growth. Understanding the fundamental mechanisms of crystallization inhibitors is relevant to a broad range of fields, including their frequent use in crystal engineering and biomineralization. This dissertation focuses on two types of pathological crystals: calcium oxalate monohydrate (COM), the primary component of kidney stones, and magnesium ammonium phosphate hexahydrate (struvite). Struvite is a key constituent of infection stones (e.g., kidney stones); and it is also a common scale in water purification and transport. Despite considerable interest in this material, the fundamental understanding of struvite growth is still at its infancy due to the lack of appropriate platforms to assess growth over multiple length scales. The use of flow systems to study infection stone formation is promising, as they can simulate the flow conditions where struvite naturally forms (e.g., urinary tract systems, catheter, pipelines, etc.). This dissertation has established a new method of evaluating struvite crystal growth under flow using a combination of microfluidics and in situ atomic force microscopy (AFM). Through these synergistic approaches, we quantified anisotropic kinetics of crystallization over a broad range of conditions and resolved the molecular mechanism of growth and its inhibition whereby layers on crystal surfaces advance from either screw dislocations or 2-dimensional generation and spreading of islands – both of which are classical pathways. Growth modifiers range from small ions and molecules to large macromolecules. Here, we examined the impact of bio-inspired small molecules on both struvite and COM crystallization. Several phosphate-based molecules exhibit an unparalleled dual mode of action capable of suppressing both nucleation and growth of crystals. Time-resolved AFM images of struvite surface at varying inhibitor concentration revealed a unique mode of crystal growth inhibition, wherein surfaces become laden with an amorphous layer that leads to roughened interfaces and growth succession through dynamic sequences that are not commonly witnessed for other minerals. In studies of COM, we observed that modifiers irreversibly stunt crystal growth in timescales that are relevant to pathological COM kidney stone formation. Comparisons between phosphate-based modifiers and two reference compounds previously identified as highly effective COM inhibitors, carboxylate-based hydroxycitrate and the urinary protein osteopontin, revealed that phosphate-based inhibitors suppress COM crystallization at substantially lower concentrations than both conventional modifiers, thus highlighting the unique efficacy of these newly evaluated bio-inspired molecules. In addition, the results presented in this dissertation address knowledge gaps that are beneficial to the development of effective inhibitors with the potential to replace existing therapeutics for these widespread maladies. Collectively, this dissertation presents research efforts aimed at inhibiting the formation of pathological crystals, focusing on an understanding of crystal growth under dynamic conditions and pathways to arrest growth via modifiers (i.e., inhibitors) that may serve as model compounds for preventative drugs.application/pdfengThe author of this work is the copyright owner. UH Libraries and the Texas Digital Library have their permission to store and provide access to this work. UH Libraries has secured permission to reproduce any and all previously published materials contained in the work. Further transmission, reproduction, or presentation of this work is prohibited except with permission of the author(s).crystal engineeringpathological mineralizationkidney stonegrowth modifier2022-06-18Thesisborn digital